Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Summary - Thomson StreetEvents

Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Summary

Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Summary - Thomson StreetEvents
Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Summary
Published Aug 03, 2023
16 pages (8758 words) — Published Aug 03, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of REGN.OQ earnings conference call or presentation 3-Aug-23 12:30pm GMT

  
Brief Excerpt:

...A. Regeneron delivered strong results across the organization in the second quarter of 2023 while continuing to make progress toward our long-term revenue and earnings streams. B. Total revenues increased by 11% compared to the prior year quarter, primarily driven by Sanofi collaboration revenues and Libtayo net product sales, which grew by 39% and 49%, respectively. C. Non-ILEA revenue contributions were 41% of total revenues. D. The highest proportion for any quarter in the last 10 years, excluding those with COVID antibody revenue contributions. E. For the remainder of my remarks today, I will focus on aflibercept 8 milligrams. F. As we announced in late June, the Complete Response Letter, or CRL, that we received from the FDA regarding our biologic license application for aflibercept 8 milligrams for the treatment of patients with wet age-related macular degeneration, DME and diabetic retinopathy did not identify any issues related to aflibercept 8 milligrams clinical efficacy, safety...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Regeneron Pharmaceuticals Inc
Ticker
REGN.OQ
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on the quarter and on the progress. Just maybe one on the itepekimab interim. Can you share anything on the futility thresholds? And if not specifically, then could you say how it sort of fared relative to BOREAS? Leonard S. Schleifer - Regeneron Pharmaceuticals, Inc. - Co-Founder, President, CEO & Co-Chairman I don't think we have anything specific. This was (inaudible) -- by the Data Safety Monitoring Committee, sort of a standard approach. We're pleased that we passed it. And we will look forward to further data at the end of the study. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 03, 2023 / 12:30PM, REGN.OQ - Q2 2023 Regeneron Pharmaceuticals Inc Earnings Call George D. Yancopoulos - Regeneron Pharmaceuticals, Inc. - Co-Founder, President, Chief Scientific Officer & Co-Chairman Yes. And both we and Sanofi are blinded to that. We only got the go decision from the independent data monitoring committee. So we'll proceed to a final readout for both of those studies.

Question: Luke Davis - RBC Capital Markets, Research Division - Analyst : This is Luke on for Brian. Can you just provide a little bit more color on what drove the Libtayo growth this quarter? Was there any stocking? Or was it largely demand-based?

Table Of Contents

Regeneron Pharmaceuticals Inc Q3 2023 Earnings Call Summary – 2023-11-02 – US$ 54.00 – Edited Brief of REGN.OQ earnings conference call or presentation 2-Nov-23 12:30pm GMT

Regeneron Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-11 – US$ 54.00 – Edited Transcript of REGN.OQ presentation 11-Sep-23 1:20pm GMT

Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference Summary – 2023-09-06 – US$ 54.00 – Edited Brief of REGN.OQ presentation 6-Sep-23 12:45pm GMT

Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript – 2023-09-06 – US$ 54.00 – Edited Transcript of REGN.OQ presentation 6-Sep-23 12:45pm GMT

Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Transcript – 2023-08-03 – US$ 54.00 – Edited Transcript of REGN.OQ earnings conference call or presentation 3-Aug-23 12:30pm GMT

Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Summary – 2023-06-14 – US$ 54.00 – Edited Brief of REGN.OQ presentation 14-Jun-23 3:40pm GMT

Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript – 2023-06-14 – US$ 54.00 – Edited Transcript of REGN.OQ presentation 14-Jun-23 3:40pm GMT

Regeneron Pharmaceuticals Inc at Jefferies Healthcare Conference Summary – 2023-06-07 – US$ 54.00 – Edited Brief of REGN.OQ presentation 7-Jun-23 12:30pm GMT

Regeneron Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript – 2023-06-07 – US$ 54.00 – Edited Transcript of REGN.OQ presentation 7-Jun-23 12:30pm GMT

Regeneron Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Summary – 2023-05-30 – US$ 54.00 – Edited Brief of REGN.OQ presentation 30-May-23 4:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Summary" Aug 03, 2023. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-Regeneron-Pharmaceuticals-Inc-Earnings-Call-B15648282>
  
APA:
Thomson StreetEvents. (2023). Regeneron Pharmaceuticals Inc Q2 2023 Earnings Call Summary Aug 03, 2023. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-Regeneron-Pharmaceuticals-Inc-Earnings-Call-B15648282>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.